Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6555 CARNEGIE AVE, 4TH FLOOR CLEVELAND OH 44103 |
Tel: | N/A |
Website: | https://abeonatherapeutics.com |
IR: | See website |
Key People | ||
Michael Amoroso Chairman of the Board | Vishwas Seshadri President, Chief Executive Officer, Director | Joseph Vazzano Chief Financial Officer | Brendan O Malley General Counsel |
Business Overview |
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company's lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Abeona Therapeutics Inc revenues increased from $1.4M to $3.5M. Net loss applicable to common stockholders increased 25% to $54.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of warrant liabilit decrease from $11.4M (income) to $11.7M (expense). |
Employees: | 84 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $110.77M as of Dec 31, 2023 |
Annual revenue (TTM): | $3.50M as of Dec 31, 2023 |
EBITDA (TTM): | -$45.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$54.19M as of Dec 31, 2023 |
Free cash flow (TTM): | -$37.34M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 38,808,934 as of May 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |